These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

592 related items for PubMed ID: 19695369

  • 1. MRI gadolinium-based contrast agents. Radiologists beware!
    Goullé JP, Cattanéo A, Saussereau E, Mahieu L, Guerbet M, Lacroix C.
    Ann Pharm Fr; 2009 Sep; 67(5):335-9. PubMed ID: 19695369
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Tissue distribution and kinetics of gadolinium and nephrogenic systemic fibrosis.
    Abraham JL, Thakral C.
    Eur J Radiol; 2008 May; 66(2):200-7. PubMed ID: 18374532
    [Abstract] [Full Text] [Related]

  • 7. [Nephrogenic systemic fibrosis and gadolinium-based contrast media].
    Andréjak M, Thuillier D, Lok C, Gras-Champel V.
    Therapie; 2007 May; 62(2):169-72. PubMed ID: 17582319
    [Abstract] [Full Text] [Related]

  • 8. Nephrogenic system fibrosis: a radiologist's practical perspective.
    Martin DR.
    Eur J Radiol; 2008 May; 66(2):220-4. PubMed ID: 18321672
    [Abstract] [Full Text] [Related]

  • 9. Extracellular Gd-CA: differences in prevalence of NSF.
    Thomsen HS, Marckmann P.
    Eur J Radiol; 2008 May; 66(2):180-3. PubMed ID: 18342468
    [Abstract] [Full Text] [Related]

  • 10. Extracellular gadolinium contrast agents: differences in stability.
    Morcos SK.
    Eur J Radiol; 2008 May; 66(2):175-9. PubMed ID: 18343072
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Nephrogenic systemic fibrosis and the role of gadolinium contrast media.
    van der Molen AJ.
    J Med Imaging Radiat Oncol; 2008 Aug; 52(4):339-50. PubMed ID: 18811757
    [Abstract] [Full Text] [Related]

  • 15. Gadolinium-containing MRI contrast agents: important variations on a theme for NSF.
    Kuo PH.
    J Am Coll Radiol; 2008 Jan; 5(1):29-35. PubMed ID: 18180006
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The impact of NSF on the care of patients with kidney disease.
    Abu-Alfa A.
    J Am Coll Radiol; 2008 Jan; 5(1):45-52. PubMed ID: 18180009
    [Abstract] [Full Text] [Related]

  • 18. Nephrogenic systemic fibrosis and its impact on abdominal imaging.
    Prince MR, Zhang HL, Prowda JC, Grossman ME, Silvers DN.
    Radiographics; 2009 Oct; 29(6):1565-74. PubMed ID: 19959508
    [Abstract] [Full Text] [Related]

  • 19. Nephrogenic systemic fibrosis: clinical spectrum of disease.
    Mayr M, Burkhalter F, Bongartz G.
    J Magn Reson Imaging; 2009 Dec; 30(6):1289-97. PubMed ID: 19937929
    [Abstract] [Full Text] [Related]

  • 20. Gadolinium use in patients with kidney disease: a cause for concern.
    Perazella MA, Rodby RA.
    Semin Dial; 2007 Dec; 20(3):179-85. PubMed ID: 17555477
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.